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Abstract Oxygen is a molecule that is central to cellular respiration and viability, yet there are multiple physiologic and
pathological contexts in which cells experience conditions of insufficient oxygen availability, a state known as hypoxia.
Given the metabolic challenges of a low oxygen environment, hypoxia elicits a range of adaptive responses at the cellular,
tissue, and systemic level to promote continued survival and function. Within this context, T lymphocytes are a highly
migratory cell type of the adaptive immune system that frequently encounters a wide range of oxygen tensions in both
health and disease. It is now clear that oxygen availability regulates T cell differentiation and function, a response
orchestrated in large part by the hypoxia-inducible factor transcription factors. Here, we discuss the physiologic scope of
hypoxia and hypoxic signaling, the contribution of these pathways in regulating T cell biology, and current gaps in our
understanding. Finally, we discuss how emerging therapies that modulate the hypoxic response may offer new modalities
to alter T cell function and the outcome of acute and chronic pathologies.
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Abbreviations
EPO Erythyropoietin
FoxP3 Forkhead box P3
HIF Hypoxia inducible factor
HRE Hypoxia response element
IBD Inflammatory bowel disease
IEL Intraepithelial lymphocyte
kPa Kilopascal
mm Hg Millimeter of mercury
PHD Prolyl hydroxylase
TCR T cell receptor
Tregs Regulatory T cells
VEGF Vascular endothelial growth factor
VHL von Hippel-Lindau
Oxygen supply and consumption
Oxygen is central to life for multicellular, eukaryotic
organisms and is required for aerobic respiration and robust
mitochondrial generation of ATP [1, 2]. In mammals,
oxygen distribution is critically regulated by the vascular
system, which continually traffics oxygen-saturated red
blood cells throughout the body. Despite this robust sys-
tem, oxygen distribution in the body is not always uniform,
with various cells and tissues transiently experiencing
periods of reduced oxygen availability, a state referred to
as hypoxia. Given the essential requirement for oxygen in
many cellular processes, and the lethal effects of oxygen
deprivation at both the tissue and organismal level, meta-
zoans have developed a tightly regulated response that
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allows for adaptation to both acute and chronic hypoxia.
Although different tissues and cells have distinct thresholds
and susceptibility to hypoxia [3], at a cellular level,
hypoxia and hypoxic responses generally occur at a
PO2 B *1 kPa (B*7–10 mm Hg or *1 % O2) [4].
In order to understand hypoxia in both physiologic and
disease states, it is important to gain an appreciation for the
basics of oxygen uptake and delivery, and the surprisingly
steep gradient of PO2 when comparing atmospheric PO2
relative to in situ PO2. At sea level, the total atmospheric
pressure is 101 kilopascals (kPa) (760 mm Hg), with 21 % of
this atmosphere comprised of oxygen, resulting in an atmo-
spheric partial pressure of oxygen (PO2) of 21.2 kPa
(159 mm Hg) [3]. Following inspiration of oxygen with each
breath, red blood cells rapidly absorb oxygen resulting in a
maximal O2 tension in the pulmonary vasculature of 13 kPa
(*98 mm Hg) [3]. As oxygen is delivered to tissue, venous
blood PO2 decreases to 5.3 kPa (*40 mm Hg). Notably,
within interstitial spaces of tissue, the average PO2 is
2.7–5.3 kPa (*20–40 mm Hg) with intracellular oxygen
tensions ranging from 1.3 to 2.7 kPa (*10–20 mm Hg). These
intracellular oxygen tensions are only a fraction of the PO2
present in normal atmospheric air and are close to the threshold
at which hypoxia and hypoxic responses generally occur at a
PO2 B *1 kPa (B*7–10 mm Hg or*1 % O2) [4].
Beyond these average baseline values, the O2 tension a
particular cell experiences is dynamically regulated by
metabolic supply and demand in the tissue and within the
cell itself. Factors that regulate this include: (i) circulatory
distance from lung oxygenation, (ii) relative proximity of
cell(s) to the vasculature, (iii) rate of local oxygen con-
sumption, and (iv) rate of oxygen consumption within the
cell. For example, a quiescent cell has very low metabolic
demands, in contrast to a highly proliferating cell (such as
an activated lymphocyte) [5]. Additionally, certain cells
(e.g., a neutrophil) have a pronounced ability to consume
oxygen via NADPH oxidase generation of reactive oxygen
species [6], which in itself can alter oxygen levels in sur-
rounding tissues and affect cellular responses.
Hypoxia occurs in a variety of physiologic
and pathologic contexts
Physiologic states of hypoxia
Hypoxia is defined as a state of reduced or inadequate
oxygen availability. Though distinct tissues and cells have
varying degrees of susceptibility to hypoxia [3], at a cel-
lular level, hypoxia and hypoxic responses generally occur
at a PO2 B *1 kPa (B*7–10 mm Hg or *1 % O2) [4].
While cells directly in the bloodstream are unlikely to
experience hypoxia except under severe pathologies, it is
noteworthy that many tissues experience low PO2 levels,
even under normal physiologic conditions. This has been
demonstrated through the use of oxygen-sensing probes in
living, anesthetized animals, where investigators found that
the mean PO2 in the thymus was 1.3 kPa (10 mm Hg),
with the majority of readings between 0 and 2.3 kPa
(0–17 mm Hg) [7]. Moreover, microelectrode measure-
ments of PO2 tensions in the spleen ranged from 0.5 to
4.5 kPa (4–34 mm Hg), depending on the relative prox-
imity to the splenic artery [8]. Further evidence for hypoxic
microenvironments has been possible through the use of
nitroimidazole-based compounds that are specifically
reduced within cells experiencing low oxygen tension
(generally PO2 \1.3 kPa or \10 mm Hg). In low oxygen
tension, these compounds generate reactive nitrogen
intermediates that form protein adducts that can be rec-
ognized by specific antibodies [6, 9] and thereby identify
cells with low oxygen tension. This method has permitted
demonstration that T cells are present in a hypoxic envi-
ronment following sepsis [10], that the bone marrow con-
tains hypoxic niches that are home to hematopoietic stem
cells [11], and that intestinal inflammation is characterized
by inflammation-associated hypoxia [12].
While a full discussion of tissues that experience con-
ditions of ‘‘physiologic hypoxia’’ (here defined as in situ
hypoxia in the resting, healthy individual) is beyond the
scope of this article, the presence of hypoxic microenvi-
ronments has been observed in a range of tissues, including
the retina, the medulla of the kidney, the epidermis of the
skin [13], the thymus [7, 11], hypoxic niches within the
bone marrow [11, 14], and even regions within the spleen
[8]. Moreover, given that the lumen of the gastrointestinal
(GI) tract is essentially anoxic (i.e., containing no oxygen),
the epithelium lining of the GI tract also demonstrates
steady state hypoxia [6].
Beyond these homeostatic/physiologic areas of hypoxia,
inflammatory sites can also be characterized as hypoxic [6].
Inflammation-associated hypoxia (or inflammatory hypoxia)
can result from a combination of factors that result in a shift
in metabolic supply and demand. First, within an inflamed
tissue, there is an accumulation of metabolically active
leukocytes. For example, in the case of intestinal inflam-
mation during chemically induced colitis, neutrophilic
infiltration into the colon and significant oxygen consump-
tion due to generation of the respiratory burst can lead to
depletion of local oxygen [6]. Additionally, during inflam-
mation, the generation of interstitial edema can increase the
intercapillary distance [3], further impairing oxygen trans-
port to cells at a site of inflammation. Oxygen consumption
also increases with elevated temperature, which is particu-
larly relevant in the context of inflammation-associated
fever [3]. All of these factors likely contribute to the
development of a hypoxic environment at inflamed sites,
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which can modulate the responses of infiltrating cells,
including T lymphocytes.
Pathologic states of hypoxia
At present, hypoxia has been identified as an important
cofactor in a wide range of pathologic states (reviewed in
[2, 15–18]; Table 1). Prominent examples of diseases in
which hypoxia is thought to have significant impact
include: (i) solid tumors, with an insufficient or irregular
vascular bed supply [19, 20], (ii) ischemic injury, including
liver or kidney ischemic injury, myocardial infarction, and
transplants [21], and (iii) obesity, in which adipose tissue
hypoxia contributes to metabolic and inflammatory chan-
ges [22]. In each of these contexts, T cells are thought to
have the capacity to influence the nature of the disease
process [23–30]. However, the specific contribution of
hypoxic signaling within T cells in these disease processes
remains poorly characterized.
Oxygen tension in T cell environments
T cells frequently encounter a wide range of oxygen ten-
sions given their highly mobile nature (Fig. 1; Table 2).
During development, thymocytes reside within the rela-
tively low oxygen environment of the thymus [7], whereas
mature T cells circulating in the blood will experience a
relatively high oxygen environment. However, depending
upon the specific localization within the spleen, some
mature T cells can also be found in hypoxic areas even
under homeostatic conditions. Furthermore, T cells present
in the lymphatic system experience a range of oxygen
tensions (*1.1–4.7 kPa or 8–35 mm Hg), the lower end of
which is sufficiently low to induce hypoxic responses,
including Hif-1a protein stabilization [31–33]). Most
certainly, effector T cells present at sites of inflammation
or retained within non-lymphoid tissues have a high
probability of prolonged exposure to a hypoxic environ-
ment. For example, in the context of human chronic
inflammatory diseases, T cells present in inflammatory
lesions in inflammatory bowel disease (Crohn’s disease and
ulcerative colitis) [34] and rheumatoid arthritis [35]
express Hif-1a. This evidence suggests that T cell
responses in the context of inflammation are likely influ-
enced by both hypoxia exposure and modulation of HIF
expression.
Oxygen-sensing machinery and the response to hypoxia
Following exposure to inadequate oxygen levels, hypoxia
triggers a multi-pronged adaptive response. For example,
exposure to high altitude and the decreased PO2 resulting
from reduced atmospheric pressure elicits an immediate
increase in respiratory rate and an increase in erythropoi-
etin (EPO) that stimulates the production of red blood cells;
these adaptations function to enhance the oxygen-carrying
capacity of the blood [36]. At a cellular level, hypoxia
induces changes in the mRNA expression of hundreds of
genes, including those involved in metabolic pathways as
well as tissue adaptive responses (e.g., increased produc-
tion of vascular endothelial growth factor, VEGF) [37, 38].
Hif-1a is a master regulator of the hypoxic response
To date, the best-characterized transcriptional effector of
the hypoxic response is Hif-1a. Hif-1a is a basic helix-
loop-helix, PAS domain containing transcription factor that
is profoundly induced by hypoxia. In hypoxia, Hif-1a
heterodimerizes with the constitutively expressed Hif-1b
Table 1 Examples of pathologic conditions characterized by hypoxia
Pathologic condition Possible causes of hypoxia Duration of hypoxia
Ischemia/reperfusion (e.g., stroke, myocardial
infarction, hepatic ischemia, renal ischemia)
Acute vessel obstruction [21] Acute (seconds–minutes)
Transplantation Transient disruption of tissue perfusion, vasculature [15] Acute (minutes–hours)
Wound healing Metabolic activity of cells at site [18] Acute (hours–days)
Cancer (solid tumors) Insufficient and irregular vascularization to solid tumor [20] Acute to chronic
Vascular disease (e.g., sickle cell disease) Impaired red blood cell trafficking and oxygen delivery [21] Acute to chronic
Obstructive sleep apnea Impaired breathing during sleep [17] Intermittent (over hours)
Chronic infection (e.g., granulomas) Metabolic activity of cells at site, tissue necrosis [16] Chronic (days–months)
Obesity Insufficient vascularization, Insufficient oxygen
diffusion due to cell size [22]
Chronic (weeks–months)
References are indicated in ‘‘Possible causes of hypoxia’’ column
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(also known as Arnt, the aryl hydrocarbon receptor nuclear
transporter) and translocates to the nucleus, where it binds
to hypoxia response elements (HREs) in the promoters of a
variety of genes [38, 39]. HIF transcriptional targets
include glycolytic machinery (e.g., Glut1, Pgk1), VEGF,
and the chemokine receptor CXCR4. While some Hif-1a
targets are conserved across multiple cell types, Hif-1a is
also clearly capable of mediating cell type-specific tran-
scriptional responses [39].
Hif-1a is regulated at multiple stages, including tran-
scriptional, translational, and post-translational levels [40].
The two best described oxygen-dependent processes that
influence Hif-1a stability and function are as follows:
(i) Hif-1a is hydroxylated on two highly conserved proline
residues by prolyl hydroxylase enzymes (PHD1-3),
which in turn allows the von Hippel–Lindau protein, an
E3 ubiquitin ligase, to bind, ubiquitinate, and target Hif-
1a for proteasomal degradation [41–43]. Notably, prolyl
hydroxylation and PHD activity are regulated by
molecular oxygen, such that in conditions of limited
oxygen availability, PHD function is inhibited, disrupt-
ing this proteolytic cascade [44].
(ii) Hif-1a is also hydroxylated in an oxygen-dependent
reaction on a highly conserved asparagine residue by
FIH-1 (Factor inhibiting HIF-1), which blocks the
ability of Hif-1a to recruit transcriptional coactivators
such as p300/CBP, in turn limiting transcriptional
activation by Hif-1a under non-hypoxic conditions
[45, 46]. Similar to the PHDs, in conditions of limited
oxygen, FIH-1 function is inhibited, disrupting
hydroxylation of this asparagine residue and allowing
for enhanced HIF transcriptional activity [44].
Based on these mechanisms, in normoxia, Hif-1a is
rapidly degraded and has limited transcriptional activation
capacity. In contrast, in limiting oxygen conditions, Hif-1a
stability and activity are substantially increased, allowing a
transcriptional response that is tightly induced in hypoxic
conditions.
Molecular regulators of the hypoxic response beyond
Hif-1a
Hif-2a was first identified as endothelial PAS domain
containing protein 1 (EPAS1), a PAS domain containing
transcription factor with 48 % identity to Hif-1a, hypoxia-
inducible expression, and HRE-binding capacity [47].
Hif-2a is an important transcriptional regulator of hypoxic
responses, controlling a variety of processes including
hypoxic regulation of EPO synthesis [48, 49] and macro-
phage function [50, 51]. The interplay between Hif-1a and
Hif-2a in hypoxic gene regulation remains an evolving
field. It is worth noting, however, that in different contexts,
these transcriptional regulators can have redundant, unique,
or antagonistic functions [52].
Beyond the HIFs, hypoxia triggers multiple transcrip-
tional cascades (reviewed in [53]). For example, hypoxia
activates the NF-kB pathway through p65 and p50 stabil-
ization and nuclear translocation that induces transcription
of many genes [54]. Interestingly, NF-kB, which is a
master regulator of inflammatory responses, is essential for
the induction of baseline Hif-1a mRNA [55], demonstrat-
ing that hypoxia, Hif-1a, and NF-kB are intimately linked
in regulating both hypoxia and inflammation. Interestingly,
in T cells, stimuli that activate NF-kB such as antigen or
cytokine stimulation also induce Hif-1a protein (see below
for more details).
Recent studies have further revealed additional molec-
ular regulators of the hypoxic response. These include:
Fig. 1 Physiologic oxygen tensions in situ are significantly lower
than atmospheric oxygen tension, with multiple tissues experiencing
‘‘physiologic hypoxia’’ during normal inspiration of atmospheric air.
Graph depicts the range of oxygen tensions in multiple tissues
(indicated at left), with published ranges of oxygen tensions indicated
by the black bar on the plot. The gray shaded area, between 0 and
2 kPa, indicates the PO2 range at which Hif-1a protein has increased
stability, a marker of the hypoxic response. The vertical dashed line
indicates a PO2 of 1.3 kPa, the PO2 at which cells generally retain
nitroimidazole compounds, indicating cells or tissues experiencing
hypoxia. Additional examples of tissues that stain positive with
nitroimidazole compounds are indicated at the bottom of the figure.
Please see text for additional details and references
Table 2 Physiologic sites where T cells may encounter low oxygen
tension
Anatomical site T cell subset
Thymus All thymocytes
Intestine Intraepithelial lymphocytes (IELs)
Skin cd T cells
Wounds cd T cells
Sites of inflammation Various
Bone marrow CD8 memory T cells
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1. hypoxic-elicited microRNAs, capable of mediating
regulatory changes at the transcriptional and post-
transcriptional level [56],
2. epigenetic modifications, mediated in part by hypoxic
induction of enzymes involved in DNA methylation
and histone acetylation. These changes are capable of
allowing new genes to be expressed in hypoxia, as well
as to repress expression of additional targets [57],
3. the production of reactive oxygen species, resulting
from perturbations in mitochondrial respiration, which
at least in certain contexts is required for the induction
of Hif-1a and the cellular hypoxic response [58–60].
The relative contribution of these various effector
mechanisms into the composite effect of hypoxia remains
an area of intense investigation, but is highly likely to
depend on particular cell type and differentiation status.
Alternative inducers of HIFs
Although hypoxia is a primary inducer of HIF protein
stabilization, non-hypoxic stimuli that disrupt the PHD/
VHL/HIF proteolytic cascade can also induce accumula-
tion of HIF. The PHD proteins require multiple cofactors
for Hif-1a prolyl hydroxylation: molecular oxygen,
2-oxoglutarate (also known as alpha-ketoglutarate), iron(II)
and vitamin C or glutathione [44]. In the case of hypoxia,
molecular oxygen becomes limiting, resulting in impaired
prolyl hydroxylation and the accumulation of Hif-1a pro-
tein. Under normoxic conditions, alternate mechanisms of
HIF stabilization can stabilize HIF by interfering with
cofactors required for the PHD prolyl hydroxylation reac-
tion [61]. Since iron(II) is required for PHD function, HIF
stabilization can be induced by iron chelators including
desferrioxamine and bacterial siderophores [62, 63]. In
addition, cobalt chloride is an effective stabilizer of Hif-1a
and can induce hypoxic responses in vivo [64]. Finally,
PHD activity is regulated by metabolites within the cell,
and elevated levels of succinate or fumarate can inhibit
PHD activity [65, 66], demonstrating that PHD enzymes
may serve as a metabolic sensor beyond the measurement
of molecular oxygen [67, 68].
Hif-1a stabilization in T cells
Hif-1a protein stabilization can occur in multiple contexts
in T cells (Fig. 2). While hypoxic exposure of T cells
results in modest Hif-1a stabilization [35], there are at least
two additional, non-conventional ways in which T cells
induce Hif-1a protein. First, T cell receptor (TCR) stimu-
lation results in robust Hif-1a protein stabilization that can
be further enhanced by combining TCR stimulation with
hypoxia [35, 69]. This increased Hif-1a protein synthesis is
mediated by the PI3 kinase/mTOR pathway [69]. TCR
activation can also induce expression of distinct splice
isoforms of Hif-1a mRNA in human and mouse T cells,
although the unique contribution of these splice isoforms to
gene regulation remains unclear [8, 70]. A second mech-
anism of Hif-1a induction in T cells is mediated by culture
with the pro-inflammatory cytokine IL-6, which activates
the STAT3 transcription factor [71]. Mechanistically, it is
unknown how this IL-6-driven Hif-1a expression integrates
with the normal proteolytic machinery that restricts Hif-1a
protein stability. In addition, it is currently unknown
whether Hif-1a stabilization after TCR stimulation results
strictly due to the pathways mentioned above, or whether
intracellular oxygen consumption following TCR activa-
tion may also contribute to Hif-1a protein expression
within activated T cells.
How oxygen availability influences T cell function
While most in vitro assays for T cell function are performed
at normal atmospheric oxygen (*21 % O2, *21.2 kPa
PO2, or *159 mm Hg), these concentrations are dramati-
cally higher than even the most oxygen-rich environment in
vivo [3]. Significantly, when T cells are activated in condi-
tions of physiologic oxygen tension (2–5 % O2,*2–5 kPa,
or*15–38 mm Hg), there are a number of changes in T cell
dynamics. First, T cells activated at physiologic O2 tension
have reduced proliferation and expansion following TCR
stimulation. Moreover, T cells shift their metabolism to
glycolysis and have an altered redox state that is more closely
aligned with that observed in vivo [72–75]. Culture in
physiologic O2 levels also alters the acquisition of CTL
functions, resulting in diminished cytokine production (IL-2,
Modest Hif-1
Hypoxia
(PO2<1.3 kPa)
Hif-1  targets
Molecular basis 
Extrinsic cue
pSTAT3
TCR + IL-6
Hif-1  mRNA
Prolonged Hif-1
IL-17A
IL-23 receptor
Pgk1
FoxP3
VEGF
PHD activity PI3K/mTOR
TCR
Pgk1
Adrenomedulin
Hif-1  mRNA
Robust Hif-1
Fig. 2 Hif-1a protein expression within T cells can be induced by
multiple mechanisms, with distinct outcomes on magnitude and
duration of Hif-1a expression. Of the three extrinsic cues known to
induce Hif-1a protein (listed in the top row of the figure), each uses a
distinct mechanism of induction. Examples of identified Hif-1a target
genes for each pathway are included
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IFN-c), yet increased VEGF production, and enhanced lytic
capacity in CD8 T cells [8].
The observation of reduced proliferation under hypoxia is
not unique to T cells. Indeed, the anti-proliferative effect of
hypoxia has long been appreciated, with proposed mecha-
nisms for this phenomenon ranging from upregulation of cell
cycle inhibitor proteins [76], to recent data demonstrating that
Hif-1a can directly interact with Mcm replication proteins to
regulate cell cycle progression [77]. In the context of T cells,
however, the molecular basis of this reduced proliferation
remains unknown, but can occur even in the context of strong
TCR signals, CD28-mediated costimulation, and addition of
exogenous IL-2 [128]. Despite these strong mitogenic con-
ditions, reduced proliferation may be influenced by hypoxia-
mediated alterations to TCR signaling in activated T cells
(e.g., impaired calcium flux due to hypoxia-mediated changes
in the Kv1.3 potassium channel) [78].
In vitro T cell cultures in physiologic O2 can also
influence T cell survival, although the overall effect of
hypoxia on apoptotic pathways in vitro is influenced by the
timing and cell type analyzed. For example, human T cells
activated in hypoxia are protected from activation-induced
cell death, potentially through hypoxic transcriptional
induction of adrenomedulin [79]. Conversely, culture of
activated human T cells at physiologic O2 can result in a
significantly elevated rate of spontaneous apoptosis in
certain T cell subsets [72].
In vitro oxygen availability also clearly influences
cytokine production. Once again, the overall effect of
hypoxia on cytokine production in vitro is influenced by
the culture conditions and cell type analyzed [8, 80]. These
studies frequently involve analysis of activated peripheral
blood T cells, a caveat that makes it difficult to determine
the specific contribution of hypoxia of specific T cell
subsets. Notably, one recent study using carefully con-
trolled preparations of naı¨ve T cells demonstrated that
culture at physiologic O2 levels increases IL-17 production
and Th17 differentiation [81], an intriguing observation
particularly in light of the increasing genetic data that
Hif-1a is required for optimal Th17 differentiation (see
below for further discussion).
While the above studies clearly demonstrate the impact of
oxygen availability on T cells, it is nonetheless clear that T
cells can still be functional in a hypoxic environment.
Indeed, T cells are able to preserve functionalities including
cytokine production even in conditions of severe metabolite
restriction including limited oxygen glucose [73].
Cell-extrinsic effects of hypoxia on T cells
Hypoxia can also affect T cells in a cell-extrinsic manner,
whether the hypoxic effect occurs in stromal cells or other
hematopoietic cell types [24, 82]. Some specific examples
include:
1. Hypoxia can induce chemokines to selectively recruit
T cell subsets. Recent work analyzing the link between
cancer, hypoxia, and tumor-protective effects demon-
strated that tumor-associated hypoxia induces the
expression of chemokine CCL28, which selectively
induces the recruitment of regulatory T cells (Tregs)
leading to induction of tumor tolerance and neoangio-
genesis [83].
2. Hypoxia can potently influence antigen-presenting
cells by altering their antigen presentation and T cell
stimulation capacity [82]. One emerging theme is that
tumor hypoxia generates macrophages that can sup-
press T cell responses. This suppressive phenotype is
mediated by hypoxic induction of arginase 1 and nitric
oxide synthase, both that restrict T cell activation.
Strikingly, induction of this hypoxic pathway in
macrophages is required for optimal tumor growth
[84, 85].
3. Hypoxia can alter target cell susceptibility to CD8 T
cell-mediated cytotoxicity as evidenced by the
increased resistance of hypoxic tumor cells to CTL-
mediated lysis. This increased resistance to CD8 T
cell-mediated killing is correlated with the hypoxic
induction of tumor cell autophagy [86, 87].
Additional cofactors in the hypoxic microenvironment
It is noteworthy that in hypoxic microenvironments, there
are often additional alterations in nutrients and metabolites,
often driven by the hypoxic response, which can influence
T cell function. Perhaps, the best example of this is the
generation of extracellular adenosine and promotion of
adenosinergic signaling as a negative feedback loop to
restrict T cell activation (reviewed in [23]). Another fre-
quent microenvironmental change with hypoxia is elevated
lactate, resulting from glycolysis, that can decrease the
local pH; there are emerging data that lactate can also
influence T cell function [88, 89].
Hypoxia-inducible factors as intrinsic regulators
of T cells
Hif-1a is essential for embryonic development and has
widespread, cell type-specific roles in vivo [90]. Given this
complexity, studies to address the role of Hif-1a in T cells
have been advanced most significantly through the analysis
of mice in which Hif-1a has been ablated specifically in T
cells. For the remainder of this review, the focus will be on
the intrinsic effects of Hif-1a on T cell responses. A
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thorough discussion of the roles of HIFs in innate immu-
nity has been recently reviewed elsewhere [82].
Hif-1a in thymocytes
To date, the genetic role of Hif-1a in thymocytes has been
primarily characterized through gain-of-function studies. An
early approach to analyze the role of HIFs in thymocytes was
to specifically delete the von Hippel–Lindau (Vhl) E3
ubiquitin ligase in thymocytes, an approach that results in the
stabilization of Hif-1a and Hif-2a [91]. Although Vhl targets
multiple proteins for proteasomal degradation, HIFs are a
major physiologic target [44]. Thymocyte deletion of Vhl
results in a pronounced deficit in thymocyte development,
with increased apoptosis of CD4?CD8? double-positive
thymocytes [91]. This phenotype is partially reversed fol-
lowing the deletion of Hif-1a on the Vhl-deficient back-
ground, indicating that constitutive Hif-1a expression in the
absence of Vhl is deleterious to normal thymocyte devel-
opment and differentiation, potentially by enhancing a cas-
pase 8-dependent apoptotic pathway [91]. Constitutive
activation of Hif-1a in Vhl-deficient thymocytes also resul-
ted in a reduced calcium response following TCR cross-
linking that resulted from increased removal of calcium from
the cytoplasm via Hif-1a-induced increases in SERCA2
calcium pumps [92]. The physiologic role of the Hif-
1a-regulated calcium response in thymocytes, however,
remains unknown.
While these early studies provided important insights
into the consequence of heightened Hif-1a activity within
the thymus, an important gap in our understanding involves
what effects Hif-1a deficiency alone has on thymocyte
development (including effects on positive and negative
selection).
Hif-1a as a negative regulator of T cell responses
Early genetic studies on the role of Hif-1a in T cells
identified Hif-1a as a potential negative regulator of T cell
responses, a concept pioneered by Michail Sitkovksy [10,
93]. The first studies on Hif-1a in T cells focused on in
vitro models of T cell activation using Hif sufficient or
deficient T cells from conditional Hif-1a KO mice, mice
lacking the activation inducible Hif-1a isoform or bone
marrow chimeras [93], and showed that Hif-1a-deficient T
cells had enhanced production of cytokines including IFN-
c and IL-2. By using a model of cecal ligation and punc-
ture, it was also determined that Hif-1a had an important
role in negatively regulating T cell function in vivo [10].
Whereas wild-type mice had a high rate of mortality fol-
lowing cecal ligation, T cell Hif-1a-deficient mice had
improved survival and decreased bacterial loads associated
with enhanced cytokine production (including IL-2 and
IFN-c), increased proliferation, and enhanced NF-kB
activity (both p50 and p65) in T cells [10].
Further evidence that Hif-1a may serve as an important
negative regulator of T cells came from a study of vascular
remodeling in mice lacking Hif-1a in T cells. Hif-
1a-deficient T cells had enhanced production of IFN-c and
IL-2 following in vitro activation; interestingly, it was also
observed that Hif-1a KO T cells produced less IL-17 (see
below). T cell-specific Hif-1a KO mice also had increased
inflammatory cell infiltration and vascular remodeling in a
vascular injury model [94]. Additionally, in vitro activation
of CD4 T cells from Hif-1a heterozygous mice demon-
strated increased IFN-c production and decreased eosino-
philia in a model of antigen-elicited airway eosinophilia
[80]. Consistent with the notion that Hif-1a can constrain T
cell responses, studies by Ben-Shoshan et al. [95] demon-
strated that hypoxia and Hif-1a can promote the tran-
scriptional induction of FoxP3, to promote the generation
of regulatory T cells (Tregs). Furthermore, our recent data
demonstrate that hypoxia enhances the abundance of Tregs
through direct transcriptional induction of FoxP3 and that
Hif-1a plays a Treg-intrinsic role in promoting Treg
function, to restrict intestinal inflammation [128].
While many of the above studies demonstrate that Hif-
1a may constrain T cell responses, one important caveat is
that the precise contribution of Hif-1a in CD4 versus CD8
T cells or in naı¨ve versus effector T cells was often not
thoroughly investigated. This latter point is particularly
important given the differential functional capacities of
naı¨ve and effector T cells [96].
Hif-1a as a regulator of Treg versus Th17
differentiation
In contrast to the above studies showing that Hif-1a can
serve as an important negative regulator of T cell respon-
ses, two recent reports identified an alternative role for Hif-
1a in T cell differentiation in promoting the production of
pro-inflammatory Th17 cells while simultaneously limiting
the generation of Tregs [71, 97]. These conclusions were
based on the observation that T cells lacking Hif-1a had
impaired Th17 differentiation and increased production of
Tregs. While the precise molecular basis for this observa-
tion differed between the two studies, both groups showed
that Hif-1a was required for the induction of experimental
autoimmune encephalitis, a Th17-driven murine model of
autoimmunity.
The above genetic studies define a wide role for Hif-1a
in T cells, with effects ranging from Hif-1a as a negative
regulator of T cell responses to Hif-1a as a positive regu-
lator of the highly pro-inflammatory Th17 subset (Table 3).
How can Hif-1a have such diverse effects on T cells?
While the molecular basis of Hif-1a regulation and targets
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in T cells remains an ongoing area of investigation, it is
important to note:
1. Hif-1a can be induced by at least 3 distinct mecha-
nisms in T cells (discussed above), with each condition
inducing Hif-1a with a different magnitude and
duration. At this time, it remains unclear what Hif-1a
regulates in each of these contexts and how Hif-1a
integrates with additional transcriptional pathways in T
cells. For example, during Th17 differentiation, Hif-1a
can be elicited by strong metabolic demands during
IL-6 driven, STAT3-dependent Th17 differentiation
[71, 97]. Conversely, Hif-1a induction in the context of
hypoxia may occur in the absence of pro-inflammatory
transcriptional pathways; in this later context, Hif-1a
induction may be more important in hypoxia-driven
Treg generation [95, 128].
2. In a broader sense, it is also important to note that T
cell function is dynamically regulated by microenvi-
ronmental cues, and integrating Hif-1a into distinct T
cell differentiation programs might be beneficial for
multiple aspects of T cells (in both promoting and
constraining inflammation). This concept of dual-
purpose transcription factors has gained significant
traction over the past three years, with an increasing
list of transcription factors now shown to regulate both
effector T cell function and regulatory T cell function,
including IRF4, STAT3, T-bet, GATA3, Bcl-6, and
Blimp-1 [98–105].
Based on this supposition, a future goal for this field of
study will be to rigorously compare diverse models of in
vitro and in vivo T cell function using Hif-1a-deficient
models to gain a true understanding for whether Hif-1a
constrains or promotes T cell inflammatory responses or
whether the role of Hif-1a in modulating T cell responses is
dependent on the T cell subset in which its expression is
activated (e.g., naı¨ve vs. effector T cell, Treg vs. Th17
cell).
Hif-1a in metabolic reprogramming of T cells
In recent years, there has been an increasing understanding
of the central importance of metabolism in regulating T
cell function [5, 106, 107]. Different subsets of T cells, as
well as different stages following T cell activation, are
characterized by the use of different metabolic pathways
[97, 108, 109]. For example, upon T cell activation, T cells
shift from a relatively metabolically quiescent state (char-
acterized primarily by catabolic metabolism) to a highly
metabolic phenotype (characterized primarily by anabolic
metabolism and the induction of aerobic glycolysis) [106].
A major function of Hif-1a in multiple cell types is the
induction of metabolic reprogramming, to shift metabolism
to glycolysis in conditions of limited oxygen availability
[110]. Despite the known role of Hif-1a in promoting
glycolysis in multiple cell types, it is noteworthy that Hif-
1a is not required for the initiation of aerobic glycolysis in
activated T cells; instead, c-Myc is uniquely required for
this metabolic shift [111]. Despite this fact, it is clear that
Hif-1a can play an important role in promoting optimal
metabolism in the case of Th17 differentiation [97].
However, more detailed and precise studies will be
Table 3 Genetic analysis of hypoxic signaling in T cells
Gene (Gene symbol) Knockout phenotype
Hif-1a (Hif1a) Thymic deficit: Reduced cellularity, unknown mechanism [91]
Peripheral T cells
(i) Enhanced pro-inflammatory cytokines after in vitro TCR stimulation [93]
(ii) Improved survival after sepsis [10]
(iii) Increased inflammation after vascular injury [94]
(iv) Impaired Treg function [128]
(v) Defect in Th17 differentiation [71, 97]
Hif-1a-I.1 Enhanced pro-inflammatory cytokines after in vitro TCR stimulation [93]
Hif-2a (Epas1) Unknown
Vhl (Vhl) Thymic deficit: Increased apoptosis (Hif-1a dependent) [91]
Thymocytes: Altered calcium signaling due to increased SERCA2 (Hif-1a dependent) [92]
PHD1 (Egln2) Unknown
PHD2 (Egln1) Unknown
PHD3 (Egln3) Unknown
FIH1 (Hif1an) Unknown
Note that loss-of-function alleles have been generated for all of these genes at an animal level. Of the indicated genes, deletion of Hif-1a, Hif-2a,
Vhl, and PHD2 results in embryonic lethality and requires the use of floxed alleles for genetic analysis
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required to elicit the specific requirements for Hif-1a in T
cell metabolism.
Hif-1a in non-conventional T cell subsets
To date, the role of Hif-1a in the regulation of other T cell
subsets including cd T cells, IELs, and NKT cells remains
unknown. Given the presence of these cell types at sites of
physiologic hypoxia (e.g., cd T cells residing in the skin
and IELs lining the anaerobic environment of the gut
lumen), it is extremely likely that hypoxic signaling
will also regulate their function and that this is a
greatly understudied, but potentially fascinating avenue of
investigation.
Hypoxic signaling in T cells beyond Hif-1a
Despite recent advances in our understanding of the role of
Hif-1a in regulating T cells, our current understanding of
hypoxic regulation in T cells remains in its relative infancy.
In particular, there is a complete lack of information on
hypoxic regulation in T cells mediated by Hif-2a, NF-kB,
or hypoxic-elicited miRNAs. Furthermore, the common
use of Hif-1b in both hypoxic signaling and the aryl
hydrocarbon receptor pathway, which regulates Th17 dif-
ferentiation and IL-10 production [112, 113], raises the
possibility of cross talk in regulating T cell function. In a
broader sense, it will also be important to understand
conserved and unique features of the hypoxic T cell
response, how it integrates with T cell receptor signaling
pathways, and whether different T cell subsets have varied
hypoxic responsiveness [114].
Therapeutic potential of the hypoxic pathway
Because of the known contributions of hypoxia to a wide
variety of pathologies, there is strong interest in developing
therapies that modulate hypoxic signaling. By disrupting
the HIF proteolytic pathway, researchers have identified
compounds that activate HIF and hypoxic signaling [115].
HIF activators have been used in a variety of in vivo
models, where they have been shown to potentiate innate
antibacterial defense mechanisms [116] and to limit
inflammation in models of inflammatory bowel disease and
LPS-induced shock [117–120]. HIF activators appear
capable of triggering multiple tissue protective pathways
that protect epithelial cells from apoptosis, elicit an
M2-like macrophage phenotype, and induce IL-10 pro-
duction in B cells [119, 120]. Although there has been
concern about the use of HIF activators systemically due to
the potential for deleterious side effects in humans, recent
phase I studies have shown that systemic treatment with
HIF activators is safe and potentially useful in boosting
EPO levels in patients with end-stage renal disease [121].
Despite these early positive therapeutic results, HIF
activators are not beneficial in all situations. For example,
while HIF activation protects against LPS-induced shock, it
is deleterious in mice subjected to polymicrobial sepsis
following cecal ligation puncture [120]. Another caveat of
current HIF activators is that many are prolyl hydroxylase
(PHD) inhibitors. Since PHDs are capable of modulating
the activity of multiple pathways including NF-kB [122],
these compounds likely have pleiotropic effects beyond
activation of HIF, which can lead to potentially unpre-
dictable side effects.
The search for possible HIF inhibitors has led to the
identification of a number of molecules that impair HIF at
various transcriptional and translational stages (ranging
from protein stabilization to dimerization to DNA binding)
[123]. One significant hurdle for the use of these com-
pounds, however, is the lack of specificity of these com-
pounds for specific blockade of HIF (such as digoxin,
acriflavine, and 17-AAG) identified to date [124–126].
Despite these caveats, therapies designed to interfere with
HIF signaling in tumors are already in clinical trials in
humans to assess antitumor efficacy [127].
With the emergence of various HIF modulators, it is
possible that these compounds may have efficacy in regu-
lating T cell responses either through the activation or
inhibition of hypoxic signaling. While a more complete
understanding of the role of hypoxic signaling in T cells
will be required to make full use of these compounds, early
experiments in mice using two distinct HIF activators have
demonstrated that these compounds can locally increase
the abundance of regulatory T cells and reduce inflamma-
tion in the context of inflammatory bowel disease [128]. As
further insights into the hypoxic regulation of T cells come
to light, pharmacologic manipulation of hypoxic signaling
may afford new opportunities to modify T cell function in
order to decrease inflammation, improve vaccine efficacy,
and potentially have efficacy in resolving clinically
important chronic viral and bacterial infections.
Conclusions
Oxygen is an important microenvironmental factor that is
dynamically regulated in conditions of health and disease.
The migratory pattern of naı¨ve and effector T cells exposes
T cells to a variety of oxygen tensions. Notably, from
development to maturity, T cells traffic through tissues in
which oxygen tensions are low enough to induce hypoxic
signaling and Hif-1a expression. In addition, data
demonstrating that Hif-1a is activated following T cell
receptor stimulation and under certain cytokine-driven
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differentiation pathways (e.g., Th17 differentiation) sug-
gest that Hif-1a might have an important role in T cell
activation and differentiation programs beyond its role in
coordinating responses to hypoxia. One major challenge in
understanding the consequence of hypoxic signaling in T
cells will be to further define the dynamic interplay
between oxygen availability, T cell differentiation pro-
grams, and T cell function. With the increasing availability
of sophisticated genetic models to interrogate the genetic
contribution of hypoxic signaling specifically in T cells,
combined with emerging pharmacologic tools that manip-
ulate the hypoxic response, the field is poised to gain major
new insights into how hypoxic signaling in T cells is reg-
ulated both in the context of immunity and a variety of
disease processes.
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